Allergan Puts Up $958M For Migraine Treatment Maker

Law360, New York (January 23, 2013, 12:12 PM EST) -- Specialty drugmaker Allergan Inc. will fork over $958 million for MAP Pharmaceuticals Inc., the company behind a new treatment for migraine headaches, to beef up its offerings aimed at alleviating the ailment, the pair said late Tuesday.

Under the deal's terms, MAP shareholders will receive $25 per share in cash, a 60 percent premium over the stock's Tuesday close. The California companies said they expected to button up the transaction — backed using a mix of on-hand cash and new debt — toward the end of...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.